ESTRO 2020 Abstract book

S575 ESTRO 2020

1 Keimyung University Dongsan Medical Center, Radiation oncology, Daegu, Korea Republic of ; 2 Samsung Medical Center, Radiation Oncology, Seoul, Korea Republic of ; 3 Inha University Hospital, Radiation Oncology, Incheon, Korea Republic of ; 4 School of Medicine- Kyungpook National University, Radiation Oncology, Daegu, Korea Republic of ; 5 Yonsei University College of Medicine, Radiation Oncology, Seoul, Korea Republic of ; 6 Seoul National University Bundang Hospital, Radiation Oncology, Seongnam, Korea Republic of ; 7 Kyung Hee University Medical Center, Radiation Oncology, Seoul, Korea Republic of ; 8 Yeungnam University College of Medicine, Radiation Oncology, Daegu, Korea Republic of ; 9 College of Medicine- The Catholic University, Radiation Oncology, Seoul, Korea Republic of ; 10 Soonchunhyang University College of Medicine, Radiation Oncology, Cheonan, Korea Republic of Purpose or Objective Korean radiation oncology group designed a multicenter retrospective study to evaluate the clinical outcomes of stereotactic body radiotherapy (SBRT) in patients with early stage non-small cell lung cancer (KROG 17-09). In this report, we will present an interim analysis of the study. Material and Methods Newly diagnosed T1-2N0M0 non-small cell lung cancer patients treated with SBRT from 2005 to 2014 were included and the patients who received additional surgery or systemic therapy were excluded. A total of 234 patients from 10 institutions were registered. The patients’ and tumor characteristics, and treatment details were retrospectively reviewed. Various SBRT schedules were used in each institution. Median radiation dose and fraction size were 60 Gy (range, 40-70) and 12 Gy (range, 5-20), respectively. The representative schedules are as follows; 60 Gy/4 fractions, 60 Gy/5 fractions, 48 Gy/4 fractions and 54 Gy/3 fractions in 67 (28.6%), 40 (17.1%), 31 (13.2%) and 16 (6.8%) patients, respectively. Results The median age was 76.5 years (range, 44-91) and the majority was male (76.9%). While 152 patients (65.0%) had an ECOG performance status of 0 to 1, 82 (35.0%) had an ECOG of 2 to 3, and 120 (51.3%) had underlying lung disease. Majority of patients (91.0%) underwent pathologic confirmation of primary tumor. The median tumor size was 25 mm (range, 7-58). According to AJCC 7 th staging system, 154 patients (65.8%) were confirmed as T1, and 80 (34.2.%) were as T2. Seventeen patients (7.3%) were confirmed as N0 using pathologic mediastinal lymph node evaluation, while the others (92.7%) were confirmed as N0 radiologically. After the median follow-up of 28.5 months, 84 patients (35.9%) had disease failure; local (involved) failure without regional or distant failure in 20 (8.5%), locoregional failure in 12 (5.1%) and distant failure in 52 (22.2%). The 3-year primary tumor control, local control, regional control and distant control was 85.5%, 79.9%, 83.3% and 75.3%, respectively. The 3-year overall survival, cancer-specific survival and disease-free survival was 54.1%, 66.9% and 43.2%, respectively. Grade ≥3 treatment- related toxicities were reported in 16 patients (6.9%). Conclusion n this analysis, we were able to report the characteristics and clinical outcomes of SBRT in patients with early stage non-small cell lung cancer. In the subsequent analysis, we will detail the patient- and treatment-related factors associated with the clinical outcomes. PO-0994 Prognostic factors in elderly patients with lung carcinoma (NSCLC) treated with curative intent J. Cacicedo 1 , J.L. Lopez-Guerra 2 , B.D. Delgado 2 , L. Martinez-Indart 3 , O. Del Hoyo 1 , R. Ortiz de Zarate 4 , D. Büchser 1 , A. Gomez-Iturriaga 1 , F. Andere 1 , I. San Miguel 1 , F. Suarez 1 , A. Gonzalez 1 , E. Mayrata 1 , A. Barcena 5 , F. Casquero 1 1 Cruces University Hospital/Biocruces Health Research

Institute, Radiation Oncology, Barakaldo, Spain ; 2 Hospital Universitario Virgen del Rocio, Radiation Oncology, Sevilla, Spain ; 3 Biocruces Health Research Institute, Department of Biostatistics, Barakaldo, Spain ; 4 Cruces University Hospital/Biocruces Health Research Institute, Physics Department, Barakaldo, Spain ; 5 University of the Basque Country, Radiology, Barakaldo, Spain Purpose or Objective Several studies indicated that the proportion of patients receiving active treatment for lung cancer decreases with advancing age. There is little evidence regarding the importance of patient clinical characteristics to guide us in deciding which is the best treatment option in this population. We analysed which patterns of treatment are commonly used with curative intent in elderly patients with non-small-cell lung carcinoma (NSCLC) and predictive factors of overall survival (OS) in daily clinical practice. Material and Methods This multicentre prospective observational study included all consecutive patients aged ≥ 65 years old diagnosed with NSCLC between February 2014 and January 2017. Inclusion criteria: age ≥ 65 years, histological diagnosis of NSCLC, stages IIIA or IIIB according to the 7 th edition TNM classification, receiving radiotherapy (RT) with radical intent with a total prescribed dose of ≥ 50 Gy, with or without previous surgery, and with or without concomitant/sequential chemotherapy (CT). All treatment decisions were taken by a multidisciplinary committee in each centre. Kaplan-Meier curves and log-rank test was used to identify clinical or treatment associated variables [gender, age >or<75 years, TNM stage, KPS score, history of heart disease and diabetes, pre-treatment weight loss, baseline haemoglobin levels, smoking and drinking habits, pre- treatment quality of life (QOL] considering EORTC QLQ- C30 and LC-13 scores, treatment modality, RT technique and dose) for prediction of OS. Results